AI Medical Services Inc., a developer of endoscopic image diagnosis support AI, is pleased to announce that Tomohiro Tada has been appointed Chairman and Yasuji Takikawa as President and Representative Director, effective June 1, 2025. As a result, AIM will be able to accelerate its business growth further on a stronger management foundation.
AIM was founded in 2017 by Tada, a clinician, with the desire to “solve problems in the field of endoscopic medicine,” and has since set forth the mission of “saving patients around the world” and has been moving forward with this goal. After about seven years of research and development as an R&D startup, the company successfully commercialized its first AI product, endoscopic image diagnosis support software (hereinafter “endoscopic AI”), in March 2024. In addition, in May 2025, the company launched a second endoscopic AI product that was improved based on feedback from the medical field on the first endoscopic AI, and has been moving toward the social implementation of endoscopic AI.
Japanese society is currently facing complex and serious issues, such as ballooning social insurance costs, a shortage of doctors, and the need to respond to work style reforms for doctors, all due to the rapidly declining birthrate and aging population. These structural changes mean that it will be difficult to provide sustainable services in the medical and healthcare fields using traditional mechanisms, and there is a strong demand for fundamental transformation through innovation.
Also Read: SCSK Corp launches “Uwell” health management service
AIM has moved from the research and development phase to the commercialization phase, and this new structure will enable the company to accelerate its efforts and decision-making toward creating more mid- to long-term value and achieve further business growth. Under this new structure, we aim to evolve into a company that provides more sustainable and impactful solutions to the structural challenges facing society and the industry.
SOURCE: PRTimes
